secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001437749-25-007998
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum appoints Diego Miralles, M.D. to board of directors
-------------------------------------------------------------

- Dr. Miralles appointed as Class II director effective March 14, 2025, term expiring at 2026 annual meeting.
- He previously served as an advisor under an agreement with monthly retainer of up to $16,000 and an option for 5,000 shares at $17.92.
- As a non-employee director, he will receive standard cash and equity compensation including an initial option grant for 29,500 shares.
- Dr. Miralles is not considered independent under Nasdaq listing standards.
- He currently serves as CEO of AZURNA Therapeutics and serves on the board of Artiva Biotherapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925007998/0001437749-25-007998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774925007998/cont20250304_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-007998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer